therapeutic action: broad-spectrum antifungal activity

Humans vs. Fungi: An Overview of Fungal Pathogens against Humans

mycolabadmin

Fungal infections are serious health threats that kill approximately 1.5 million people annually worldwide. This comprehensive review identifies over 280 different fungal species that can infect humans, with Aspergillus being the most dangerous genus. The study provides updated information on how these infections are diagnosed through various methods including cultures, microscopy, and molecular testing, as well as treatment options ranging from traditional antifungal drugs to newer therapies like nanotechnology-based formulations.

Read More »

Identification and antifungal susceptibility patterns of reference yeast strains to novel and conventional agents: a comparative study using CLSI, EUCAST and Sensititre YeastOne methods

mycolabadmin

Researchers compared three different laboratory methods for testing how well antifungal drugs work against common yeast infections. They tested 22 different yeast strains including Candida species using CLSI, EUCAST, and Sensititre YeastOne methods. The methods showed strong agreement overall, but some newer antifungal drugs like ibrexafungerp showed more variation between methods. The findings suggest these methods are reliable for guiding treatment decisions, but further standardization is needed for newer drugs.

Read More »

Liposomal amphotericin B prophylaxis in paediatrics: a systematic review

mycolabadmin

This study reviews how a fungal medication called liposomal amphotericin B is used to prevent serious fungal infections in children with weakened immune systems, particularly those with blood cancers or who have had bone marrow transplants. The researchers found that this medicine prevents infections in about 93% of children, though it does cause side effects like low potassium levels in about 23% of patients. However, the study shows that current use of this medicine is quite varied and more high-quality research is needed to determine the best dosing approach.

Read More »

In vitro activity of SF001: a next-generation polyene versus amphotericin B

mycolabadmin

This study tested a new antifungal drug called SF001 against a well-established antifungal called amphotericin B. Researchers tested both drugs against common fungal infections affecting vulnerable patients. SF001 was found to work as well as or better than amphotericin B, particularly against harder-to-treat Aspergillus fungi, while potentially causing fewer side effects.

Read More »
Scroll to Top